Infectious Diseases - PART 3

Question 1

DAPTOMYCIN COVERAGE

Answer 1

MOST GP BACTERIA (MRSA, VRE)
NO GN ACTIVITY

Question 2

WHEN SHOULD YOU NOT USE DAPTOMYCIN

Answer 2

PNEUMONIA
INACTIVATED BY LUNG SURFACTANT

Question 3

DAPTOMYCIN INDICATIONS

Answer 3

SSTI
STAPH BLOODSTREAM INFECTIONS (MRSA)
ENDOCARDITIS

Question 4

DAPTOMYCIN WARNING

Answer 4

MYOPATHY AND RHABDOMYOLYSIS
FALSE ↑ PT/INR

Question 5

LINEZOLID COVERAGE

Answer 5

MRSA AND VRE

Question 6

LINEZOLID RENAL DOSE ADJUSTMENT?

Answer 6

NOT NEEDED

Question 7

LINEZOLID BIOAVAILABILITY

Answer 7

IV:PO 1:1

Question 8

LINEZOLID CONTRAINDICATION

Answer 8

DO NOT USE WITHIN 2 WEEKS OF MAOI

Question 9

LINEZOLID WARNING

Answer 9

DURATION RELATED MYELOSUPPRESSION (THROMBOCYTOPENIA)
OPTIC NEUROPATHY
SEROTONIN SYNDROME
HYPOGLYCEMIA

Question 10

LINEZOLID SUSPENSION. ADMINISTRATION

Answer 10

DO NOT SHAKE

Question 11

QUINUPRISTIN/DALFOPRISTIN SIDE EFFECTS

Answer 11

ARTHRALGIAS/MYALGIAS
INFUSION REACTIONS
HYPERBILIRUBINEMIA

Question 12

QUINUPRISTIN/DALFOPRISTIN ADMINISTRATION

Answer 12

DILUTE WITH D5W ONLY
ADMINISTER VIA CENTRAL LINE ONLY

Question 13

TIGECYCLINE COVERAGE

Answer 13

BROAD SPECTRUM GP (MRSA, VRE)
GN BACTERIA, ANAEROBES, ATYPICAL

Question 14

QUINUPRISTIN/DALFOPRISTIN COVERAGE

Answer 14

MRSA
VRE (BUT NOT E.FAECALIS)

Question 15

QUINUPRISTIN/DALFOPRISTIN IS NOT WELL TOLERATED, SO ONLY USED FOR THIS INFECTION

Answer 15

VRE E.FAECIUM INFECTIONS

Question 16

TIGECYCLINE DOES NOT HAVE COVERAGE TO

Answer 16

3 P’S
PSEUDOMONAS
PROTEUS
PROVIDENCIA

Question 17

TIGECYCLINE HAS LIMITED USES
WHAT ARE THE INDICATIONS?

Answer 17

COMPLICATED SSTI
INTRA-AB INFECTION
CA-PNEUMONIA

Question 18

TIGECYCLINE BOXED WARNING

Answer 18

↑ RISK OF DEATH
ONLY USE WHEN NECESSARY

Question 19

DO NOT USE TIGECYCLINE FOR THSES INFECTIONS

Answer 19

BLOODSTREAM INFECTIONS
DOES NOT ACHIEVE ADEQUATE CONCENTRATIONS

Question 20

WHAT COLOR SHOULD TIGECYCLINE BE WHEN RECONSTITUTED

Answer 20

YELLOW-ORANGE COLOR

Question 21

POLYMIXINS ARE PRIMARILY USED FOR

Answer 21

MDR GRAM NEGATIVE PATHOGENS

Question 22

POLYMIXIN WARNING

Answer 22

NEPHROTOXICITY
NEUROTOXICITY THAT CAN LEAD TO RESPIRATORY PARALYSIS

Question 23

CHLORAMPHENICOL BOXED WARNING

Answer 23

SERIOUS AND FATAL BLOOD DYSCARIAS

Question 24

CHLORAMPHENICOL WARNING

Answer 24

GRAY SYNDROME WITH HIGH SERUM LEVELS: CIRUCULATORY COLLAPSE, CYANOSIS, ACIDOSIS,COMA, DEATH

Question 25

CLINDAMYCIN COVERAGE

Answer 25

MOST GP BACTERIA (SOME CA-MRSA)
ANAEROBES
NO GN COVERAGE

Question 26

CLINDAMYCIN RENAL DOSE ADJUSTMENT NEEDED?

Answer 26

NOT NEEDED

Question 27

CLINDAMYCIN BOXED WARNING

Answer 27

COLITIS (C.DIFF)

Question 28

WHAT TEST SHOULD BE PERFORMED PRIOR TO USING CLINDAMYCIN ON S.AUREUS?

Answer 28

INDUCTION TEST (D-TEST)
TEST IF BUG WILL INDUCE RESISTANCE

Question 29

CLINDAMYCIN COMMON USE

Answer 29

PURULENT AND NON-PURULENT SKIN INFECTIONS
DENTAL ABSCESSES (BETA LACTAM ALTERNATIVE)

Question 30

METRONIDAZOLE COVERAGE

Answer 30

ANAEROBES AND PROTOZOAL INFECTIONS

Question 31

METRONIDAZOLE IS EFFECTIVE IN THESE INFECTIONS

Answer 31

BACTERIAL VAGINOSIS
TRICHOMONIASIS
IN COMBO FOR INTRA-AB INFECTIONS

Question 32

METRONIDAZOLE BIOAVAILABILITY

Answer 32

IV:PO 1:1

Question 33

METRONIDAZOLE CONTRAINDICATIONS

Answer 33

PREGNANCY 1ST TRIMESTER
ALCOHOL OR PROPYLENE GLYCOL CONTAINING PRODUCTS DURING OR WITHIN 3 DAYS OF TREATMENT D/C

Question 34

FIDAXOMIXIN IS ONLY INDICATED FOR

Answer 34

C.DIFF
NOT EFFECTIVE FOR SYSTEMIC INFECTIONS

Question 35

RIFAXIMIN HAS 4 MAIN INDICATIONS

Answer 35

TRAVELER’S DIARRHEA
↓ RECURRENCE OF HEPATIC ENCEPHALOPATHY
IBS-D
C.DIFF (OFF-LABEL)

Question 36

RIFAXIMIN BIOAVAILABILITY

Answer 36

<1% ABSORPTION
NOT EFFECTIVE FOR SYSTEMIC INFECTIONS

Question 37

FOSFOMYCIN COVERAGE

Answer 37

E.COLI (INCLUDING ESBL)
F.FAECALIS (INCLUDING VRE)

Question 38

FOSFOMYCIN INDICATION AND DOSING

Answer 38

SINGLE DOSE REGIMEN FOR UNCOMPLICATED UTI

Question 39

FOSFOMYCIN PACKET GRANULES CONTAIN HOW MANY GRAMS

Answer 39

3 GRAMS PER PACKET

Question 40

NITROFURANTOIN USE

Answer 40

UTI (CYSTITIS ONLY)

Question 41

NITROFURANTOIN COVERAGE

Answer 41

E.COLI
KLEBSIELLA
ENTEROBACTER
S.AUREUS
ENTEROCOCCUS (VRE)

Question 42

WHAT IS THE DRUG OF CHOICE FOR UNCOMPLICATED UTI

Answer 42

NITROFURANTOIN

Question 43

MICROBID VS MICRODANTIN

Answer 43

MACROBID IS BID DOSING
MACRODANTIN IS QID DOSING

Question 44

MACROBID DOSING FOR UNCOMPLICATED UTI

Answer 44

100 MG BID X 5 DAYS

Question 45

NITROFURANTOIN CONTRAINDICATIONS

Answer 45

RENAL IMPAIRMENT < 60

Question 46

NITROFURANTOIN WARNING

Answer 46

HEMOLYTIC ANEMIA IN G6PD DEFICIENCY

Question 47

RIFAMPIN SIDE EFFECTS

Answer 47

↑ LFTS
HEMOLYTIC ANEMIA (POSITIVE COMMBS TEST)
FLU LIKE SX
ORANGE-RED DISCOLORATION OF SECRETIONS

Question 48

ISONIAZID: WHAT VITAMIN SHOULD BE TAKEN WITH THIS AGENT AND WHY?

Answer 48

PYRIDOXINE (VITAMIN B6)
TO ↓ RISK OF INH-ASSOCIATED PRIPPHERAL NEUROPATHY

Question 49

ISONIAZID BOXED WARNING

Answer 49

HEPATITIS

Question 50

ISONIAZID WARNING

Answer 50

PERIPHERAL NEUROPATHY (RECOMMENDED TO TAKE PYRIDOXINE AS SUPPLEMENTAL)

Question 51

ISONIAZID SIDE EFFECTS

Answer 51

↑ LFTS
DILE
HEMOLYTIC ANEMIA

Question 52

PYRAZINAMIDE WARNING

Answer 52

ACUTE GOUT CAUSED BY HYPERURICEMIA/GOUT

Question 53

ETHAMBUTOL WARNINGS

Answer 53

OPTIC NEURITIS
CONFUSION AND HALLUCINATIONS

Question 54

PHENAZOPYRIDINE